USA flag logo/image

An Official Website of the United States Government

Gene Expression and Diagnosis of Autoimmune Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65878
Program Year/Program:
2003 / STTR
Agency Tracking Number:
AI053984
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARTHROCHIP, LLC
ARTHROCHIP, LLC 117 BROMLEY PARK LN FRANKLIN, TN 37069
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Gene Expression and Diagnosis of Autoimmune Disease
Agency: HHS
Contract: 1R41AI053984-01
Award Amount: $133,756.00
 

Abstract:

DESCRIPTION (provided by the applicant): Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, and multiple sclerosis, are thought to arise from abnormalities of innate or adaptive immune responses. Autoimmune diseases are often difficult to diagnose, as the symptoms can be typical of other conditions and quite vague, such as musculoskeletal complaints and pain, headaches or dizziness. No available blood test can accurately exclude the possibility of an autoimmune disease in a subject with these symptoms. At best, a battery of tests and a period of observation are usually required to establish that a patient does in fact have an autoimmune disorder. Thus, a single test that could readily exclude the possibility of an autoimmune disease would allow physicians to focus their efforts on patients who have the greatest likelihood of serious disease. Using microarray technology, we have compared differences in gene expression in peripheral blood mononuclear cells among individuals with four distinct autoimmune diseases, normal control individuals before and after immunization, and individuals with other chronic diseases. Surprisingly, we find that each individual with autoimmune disease has a common gene expression signature that is independent of the specific autoimmune disease but is totally distinct from the normal immune response and is not observed in individuals with other chronic diseases. Based upon these observations, we have developed a simple test for excluding the possibility that a subject has an autoimmune disorder. The main advantage of this test is that it is a quicker and more accurate test than those currently available. This test has thus far predicted autoimmune patients from normal patients with 100 percent accuracy. The first goal of this proposal is to collect gene expression data from a sufficient number of individuals to design a test with optimal predictive power. The second goal is to validate the test by examining a cohort of individuals who do not yet carry a clear-cut diagnosis of an autoimmune disease. Long-term goals are to use results from microarray experiments to develop tests that have predictive value for the therapeutic management of individuals with autoimmune diseases. These include tests that classify diseases, predict severity, and predict the best therapeutic options.

Principal Investigator:

Thomas M. Aune
6153437353
THOMAS.AUNE@VANDERBILT.EDU

Business Contact:

Thomas Aune
6153434208
THOMAS.AUNE@MCMAIL.VANDERBILT.EDU
Small Business Information at Submission:

Arthrochip, LLC
117 BROMLEY PARK LN 117 BROMLEY PARK LN Franklin, TN 37069

EIN/Tax ID: 412068541
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
VANDERBILT UNIVERSITY
3319 West End Ave.
Nashville, TN 37203
RI Type: Nonprofit college or university